IP, M&A, life sciences and competition partners advised on deal that brings together brands such as ‘Huggies’ and ‘Kleenex’ ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

In this piece, we will look at the stocks Jim Cramer discussed.

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling Palantir - whose stock has more than doubled this year on AI excitement and ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a huge consumer ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

Palantir Technologies, which came into the day with a stunning 165% gain for the year so far, rose another 3.3%. Traders ...

On Monday, gains for Nvidia, Amazon and other AI superstars propped up share prices. The S & P 500 rose 0.2% and pulled closer to its all-time high set last week, even though the majority of stocks in ...

As equity markets face sustained volatility, investors are actively seeking high-quality assets that can withstand economic ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health ...